Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06427941 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
A Phase 1 study of Metastatic Hepatocellular Carcinoma and Local Advanced Hepatocellular Carcinoma, sponsored by BeOne Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
- 19
- Study locations
NCT06427941 is a Phase 1 study of Metastatic Hepatocellular Carcinoma and Local Advanced Hepatocellular Carcinoma that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 140 participants, above the 91-participant average among 11 other Metastatic Hepatocellular Carcinoma trials with a reported enrollment target (54% higher). The trial reports 19 study locations across 14 states.
The verdict
NCT06427941, a Phase 1 study of Metastatic Hepatocellular Carcinoma and Local Advanced Hepatocellular Carcinoma, is actively recruiting participants, sponsored by BeOne Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
- 19
- Study locations
Study Summary
This is a first-in-human (FIH) clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of BGB-B2033 administered as monotherapy and in combination with tislelizumab, with or without bevacizumab. The study will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC), alpha-fetoprotein (AFP)-producing gastric cancer (GC), extragonadal yolk sac tumors/non-dysgerminomas, or glypican-3 (GPC3)-positive squamous non-small cell lung cancer (NSCLC).
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Tislelizumab
- DRUG BGB-B2033
Study Locations (19)
Seoul Teugbyeolsi
- Samsung Medical Center - GangnamGu
- Severance Hospital Yonsei University Health System - SeodaemunGu
- Seoul National University Hospital - Seoul
Jiangxi
- The Second Affiliated Hospital of Nanchang University - Nanchang
- The Second Affiliated Hospital of Nanchang Universityhongjiaozhou Branch - Nanchang
Other
- Auckland City Hospital - Auckland
- Hospital Oncologico - Rio Piedras
Gyeonggi-do
- Cha Bundang Medical Center, Cha University - BundangGu SeongnamSi
- Seoul National University Bundang Hospital - Seongnam-si
New York
- Memorial Sloan Kettering Cancer Center Mskcc - New York
Pennsylvania
- Upmc Hillman Cancer Center(Univ of Pittsburgh) - Pittsburgh
Tennessee
- Scri Oncology Partners - Nashville
Anhui
- Anhui Provincial Hospital - Hefei
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2024-07-23 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06427941
The ClinicalTrials.gov registry entry for NCT06427941 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 91-participant average among 11 other Metastatic Hepatocellular Carcinoma trials with a reported enrollment target (54% higher). The listed sponsor is BeOne Medicines, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Metastatic Hepatocellular Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT06427941 reports 19 study locations spanning 14 distinct geographic areas - top geographies include Seoul Teugbyeolsi, Jiangxi, Other.
Frequently Asked Questions
What is clinical trial NCT06427941 about?
NCT06427941 is a clinical study titled "A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors". This is a first-in-human (FIH) clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of BGB-B2033 administered as monotherapy and in combination with tislelizumab, with or without bevacizumab. The study will enroll partici...
What is the current status of trial NCT06427941?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2024-07-23. Estimated completion is 2026-12-31.
What conditions does trial NCT06427941 study?
This clinical trial studies the following conditions: Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors, Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer.
What interventions are being tested in trial NCT06427941?
The interventions under investigation include: Bevacizumab (DRUG), Tislelizumab (DRUG), BGB-B2033 (DRUG).
Who is sponsoring clinical trial NCT06427941?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06427941 being conducted?
This trial has 19 study locations across New York, Pennsylvania, Tennessee, Anhui, Fujian. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
RECRUITING · Phase 1
-
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
RECRUITING · Phase 1
-
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
RECRUITING · Phase 1
-
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
RECRUITING · Phase 1
-
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies
RECRUITING · Phase 1
-
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Metastatic Hepatocellular Carcinoma
All registered trials for this condition
Local Advanced Hepatocellular Carcinoma
All registered trials for this condition
New York
All trials with a study site in New York
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.